The role of thrombospondins in wound healing, ischemia, and the foreign body reaction
Tóm tắt
Từ khóa
Tài liệu tham khảo
Agah A, Kyriakides TR, Lawler J, Bornstein P (2002) The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161:831–839
Agah A, Kyriakides TR, Letrondo N, Bjorkblom B, Bornstein P (2004) Thrombospondin 2 levels are increased in aged mice: consequences for cutaneous wound healing and angiogenesis. Matrix Biol 22:539–547
Agah A, Kyriakides TR, Bornstein P (2005) Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 167:81–88
Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20:86–100
Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116:217–224
Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD (2008) Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 26:5583–5588
Basile DP (1999) The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens 8:21–30
Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167–32173
Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63:5224–5229
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744
Brechot N, Gomez E, Bignon M, Khallou-Laschet J, Dussiot M, Cazes A, Alanio-Brechot C, Durand M, Philippe J, Silvestre JS, Van Rooijen N, Corvol P, Nicoletti A, Chazaud B, Germain S (2008) Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS ONE 3:e3950
Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170
Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707–717
Detmar M (2000) The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24(Suppl 1):S78–84
DiPietro L, Nissen N, Gamelli R, Koch A, Pyle J, Polverini P (1996) Thrombospondin 1 synthesis and function in wound repair. Am J Pathol 148:1851–1860
Emonard H, Bellon G, Troeberg L, Berton A, Robinet A, Henriet P, Marbaix E, Kirkegaard K, Patthy L, Eeckhout Y, Nagase H, Hornebeck W, Courtoy PJ (2004) Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem 279:54944–54951
Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807–818
Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP (1999) Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147–158
Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK (2001) The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem 276:15498–15503
Heil M, Schaper W (2004) Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 95:449–458
Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W (2006) Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 10:45–55
Hiscott P, Paraoan L, Choudhary A, Ordonez JL, Al-Khaier A, Armstrong DJ (2006) Thrombospondin 1, thrombospondin 2 and the eye. Prog Retin Eye Res 25:1–18
Hoefer IE, van Royen N, Jost MM (2006) Experimental models of arteriogenesis: differences and implications. Lab Anim (NY) 35:36–44
Hugo C (2003) The thrombospondin 1-TGF-beta axis in fibrotic renal disease. Nephrol Dial Transplant 18:1241–1245
Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD (2005) Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102:13141–13146
Isenberg BC, Williams C, Tranquillo RT (2006a) Small-diameter artificial arteries engineered in vitro. Circ Res 98:25–35
Isenberg J, Ridnour L, Dimitry J, Frazier W, Wink D, Roberts D (2006b) CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281:26069–26080
Isenberg J, Jia Y, Fukuyama J, Switzer C, Wink D, Roberts D (2007a) Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282:15404–15415
Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD (2007b) Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109:1945–1952
Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD (2007c), Thrombospondin-1 stimulates platelet aggregation by blocking the anti-thrombotic activity of nitric oxide/cGMP signaling. Blood 613-623
Isenberg JS, Frazier WA, Roberts DD (2008a) Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci 65:728–742
Isenberg JS, Roberts DD, Frazier WA (2008b), CD47. A New Target in Cardiovascular Therapy. Arterioscler Thromb Vasc Biol 615-621
Isenberg J, Annis D, Pendrak M, Ptaszynska M, Frazier W, Mosher D, Roberts D (2009) Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284:1116–1125
Jackson J, Seed M, Kircher C, Willoughby D, Winkler J (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465
Jenkins G (2008) The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 40:1068–1078
Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41–48
Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, Bornstein P, Jin DK, Marcus AJ, Rafii S (2006) Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 116:3277–3291
Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, Bornstein P, Sessa WC, Kyriakides TR (2008) Thrombospondin-2 Modulates Extracellular Matrix Remodeling during Physiological Angiogenesis. Am J Pathol 173:879–891
Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90:986–992
Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang ZT, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P (1998a) Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 140:419–430
Kyriakides TR, Zhu YH, Yang Z, Bornstein P (1998b) The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J Histochem Cytochem 46:1007–1015
Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD, Bornstein P (1999a) Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci USA 96:4449–4454
Kyriakides TR, Tam JW, Bornstein P (1999b) Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787
Kyriakides T, Hartzel T, Huynh G, Bornstein P (2001a) Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. Mol Ther 3:842–849
Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P (2001b) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255–1262
Kyriakides TR, Rojnuckarin P, Reidy MA, Hankenson KD, Papayannopoulou T, Kaushansky K, Bornstein P (2003) Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood 101:3915–3923
Kyriakides TR, Wulsin D, Skokos EA, Fleckman P, Pirrone A, Shipley JM, Senior RM, Bornstein P (2009) Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol 28:65–73
Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian UH, Bornstein P, Detmar M (2002) Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice. Blood 99:538–545
Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO (1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982–992
Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691
Lin TN, Kim GM, Chen JJ, Cheung WM, He YY, Hsu CY (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34:177–186
Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H (2003) Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol 23:5401–5408
Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4:140–156
MacLauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR (2009) Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem 57:301–313
Murphy-Ullrich JE, Poczatek M (2000) Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11:59–69
Oganesian A, Armstrong L, Migliorini M, Strickland D, Bornstein P (2008) Thrombospondins Use the VLDL Receptor and a Nonapoptotic Pathway to Inhibit Cell Division in Microvascular Endothelial Cells. Mol Biol Cell 19:563–571
Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221–233
Puolakkainen PA, Bradshaw AD, Brekken RA, Reed MJ, Kyriakides T, Funk SE, Gooden MD, Vernon RB, Wight TN, Bornstein P, Sage EH (2005) SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J Histochem Cytochem 53:571–581
Raugi G, Olerud J, Gown A (1987) Thrombospondin in early human wound tissue. J Invest Dermatol 89:551–554
Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE (1999) The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274:13586–13593
Sakai K, Sumi Y, Muramatsu H, Hata K, Muramatsu T, Ueda M (2003) Thrombospondin-1 promotes fibroblast-mediated collagen gel contraction caused by activation of latent transforming growth factor beta-1. J Dermatol Sci 31:99–109
Schonbeck U, Mach F, Libby P (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161:3340–3346
Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 269:26783–26788
Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270:7304–7310
Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34
Streit M, Velasco P, Riccardi L, Spencer L, Brown L, Janes L, Lange-Asschenfeldt B, Yano K, Hawighorst T, Iruela-Arispe L, Detmar M (2000) Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 19:3272–3282
Suzuma K, Takagi H, Otani A, Oh H, Honda Y (1999) Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol 154:343–354
Tang Y, Scheef EA, Wang S, Sorenson CM, Marcus CB, Jefcoate CR, Sheibani N (2009) CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood 113:744–754
Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R (1997) The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8:471–479
Tian W, Kyriakides TR (2009) Thrombospondin 2-null mice display an altered brain foreign body response to polyvinyl alcohol sponge implants. Biomed Mater 4:15010
Uno K, Hayashi H, Kuroki M, Uchida H, Yamauchi Y, Oshima K (2004) Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem Biophys Res Commun 315:928–934
Velasco P, Huegel R, Brasch J, Schroder JM, Weichenthal M, Stockfleth E, Schwarz T, Lawler J, Detmar M, Lange-Asschenfeldt B (2009) The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. J Invest Dermatol 129:2022–2030
Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N (2003) Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 228:630–642
Yan J, Zeng Y, Zhou J, Yin Z, Wang Z, Zhu P (2007) The expression patterns of vascular endothelial factor and thrombospondin 2 after corneal alkali burn. Colloids Surf B Biointerfaces 60:105–109
Yang Z, Kyriakides TR, Bornstein P (2000) Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell 11:3353–3364
Yang Z, Strickland DK, Bornstein P (2001) Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276:8403–8408
Yano K, Oura H, Detmar M (2002) Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol 118:800–805
Yano K, Brown L, Lawler J, Miyakawa T, Detmar M (2003) Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J Invest Dermatol 120:14–19
Yano K, Kajiya K, Ishiwata M, Hong Y, Miyakawa T, Detmar M (2004) Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. J Invest Dermatol 122:201–208
Yano K, Kadoya K, Kajiya K, Hong Y, Detmar M (2005) Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 152:115–121
Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165:541–552
Young GD, Murphy-Ullrich JE (2004) The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 279:47633–47642